Background: Following the example of l-valine prodrugs of antiviral nucleoside analogues, l-valine ester of cyclopropavir (valcyclopropavir) was synthesized. Methods: The known tetrahydropyranylcyclopropavir was transformed to N-(tert-butoxycarbonyl)-l-valine ester, which was deprotected to valcyclopropavir. Results: Stability of valcyclopropavir towards hydrolysis at pH 7.0 roughly corresponded to that of valganciclovir.
Efficacy of antiviral nucleoside analogues is often hampered by their low solubility and bioavailability. To address this deficiency, several types of prodrugs have been synthesized [1] . Amino acid esters were found to be especially advantageous. Valine ester prodrugs of acyclovir (valacyclovir [Valtrex] (1)) [2] [3] [4] and ganciclovir (valganciclovir [Valcyte] (2); Figure 1 ) [5, 6] are already part of our armament for fighting infections caused by herpes simplex virus type-1 and type-2, varicella zoster virus and human cytomegalovirus (HCMV). An additional advantage of these prodrugs resides in their ability to facilitate the membrane transport by using the peptide transporters [6, 7] PEPT1 and PEPT2. l-Valine ester prodrugs are readily hydrolysed by chemical or esterase-catalysed hydrolysis and/or a biphenyl hydrolase-like protein (valaciclovirase) [8] . More recently, this approach has been extended to the nucleoside analogue 2′-deoxy-l-cytidine (l-dC) [9] , which is effective against hepatitis B virus and 2′-C-methylcytidine [10] , which is an anti-hepatitis C virus agent. Both l-valine esters, Val-l-dC (valtorcitabine (3)) [11] and valopicitabine (4) [12] have improved pharmacokinetic profiles over their parent analogues.
In our laboratory, we have developed a new class of antiviral agents that are methylenecyclopropane analogues of nucleosides [13] . Among these analogues, cyclopropavir (5) exhibits antiviral parameters superior to ganciclovir [14] [15] [16] and it is a subject of current preclinical studies. In order to improve therapeutic efficacy of cyclopropavir (5) , we have turned our attention to the l-valine ester valcyclopropavir (6) . The synthesis, antiviral activity and pharmacokinetic parameters of analogue 6 are the subject of this communication.
Methods

Synthesis
The mass spectra (MS) were determined in an electrospray ionization (ESI) mode. Valcyclopropavir (6) was synthesized as described below. Cyclopropavir (5) was synthesized by GLSynthesis, Inc. (Worcester, MA, USA) by a previously published method [14] . All other chemicals were of an analytical reagent grade and all solvents were of an HPLC grade. 2)). (B) Synthesis of valcyclopropavir (6) . a Yan et al. [17] . b N-(tert-butoxycarbonyl)-l-valine anhydride, 4-dimethylaminopyridine and N,N-dimethylformamide. c 10% HCl in ethyl acetate. 
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Antiviral assays
Plaque reduction assays in human foreskin fibroblasts were performed with HCMV Towne and AD169 strains as previously described [14, 15] .
Stability of the prodrug valcyclopropavir (6) in mouse plasma and whole blood
Male Swiss-Webster mice (Taconic Farms, Germantown, PA, USA) were anaesthetized and blood was collected (1 ml per animal) by cardiac puncture into Monoject ® collection tubes (number 8881-311149; Tyco Healthcare, Mansfield, MA, USA), containing an anticoagulant (0.04 ml of 7.5% EDTA[K 3 ]). The blood was cooled in ice and used immediately for plasma preparation and stability studies. For plasma preparation, half of the collected blood was centrifuged for 10 min at 1,100 g in a refrigerated centrifuge (4°C). For stability at 0°C, ice cooled blood and plasma samples were spiked with a 10 mM solution of the prodrug (6) in DMSO to a final concentration of 50 µM. The Compound, % Cyclopropavir (5) Valcyclopropavir (6) samples were kept in ice water. For stability at 37°C, the plasma and blood samples were brought to 37°C by placing them in warm water, and then in a thermostatic water bath. Aliquots of 200 µl plasma and 400 µl blood were taken at the indicated times. The plasma samples were frozen immediately in a dry ice/acetone mixture. The blood samples were centrifuged in a refrigerated centrifuge (4°C) for 5 min at 2,200 g. Plasma (150 µl) was removed, frozen in a dry ice/acetone mixture and stored at -20°C until analysed. The samples were analysed for valcyclopropavir (6) and cyclopropavir (5) by the HPLC method describe below.
Bioavailability of cyclopropavir (5) after intravenous and oral dosing of the prodrug valcyclopropavir (6) to mice
Dosing and blood sampling of mice Prodrug (6) was dissolved in physiological saline at 4.92 mg/ml. Male Swiss-Webster mice (n=3 per group per time point) received intravenous (IV) injection via the tail vein at a dose of 24.6 mg/kg (5 ml/kg, ca. 140 µl per animal), or given orally by gavage (IO) at a dose of 49.2 mg/kg (10 ml/kg, ca. 300 µl per animal). Mice given the IV dose had a mean body weight of ca. 28 g. Mice given the IO dose were fasted overnight before dosing and had a mean body weight on the day of dosing of ca. 30 g. At the indicated sampling times, (10, 20, 40, 80, 160 and 240 min for IV mice and 20, 40, 60, 120, 240 and 320 min for IO mice), animals were anaesthetized and sacrificed, and blood was collected by cardiac puncture. Blood samples were cooled on ice and immediately subjected to centrifugation at 4°C for plasma preparation. The plasma samples were frozen on dry ice and stored at -20°C until analysed.
Analytical methods
Preparation of standard solutions and spiked plasma calibration samples
Six standard solutions containing a mixture of pro drug (6) and cyclopropavir (5) at concentrations of 0.6, 2.0, 6.0, 20.0 and 60.0 µg/ml were prepared by diluting DMSO stock solutions (10 mg/ml) with acetonitrile. For spiked plasma calibration samples, aliquots of 250 µl of the standard solutions were mixed with equal volume of mouse plasma in polypropylene microfuge tubes. For extraction efficiency determination, another set of standard solutions (250 µl) were mixed with an equal volume of water. All tubes were vortexed for 30 s, maintained at room temperature for 30 min, vortexed again for 30 s and then centrifuged for 15 min at 13,000 rpm. The supernatants (375 µl each) were pipetted from each tube into a new microfuge tube and evaporated to dryness in a Speed Vac (4-5 h; Savant, Nassau-Suffolk, NY, USA). DMSO (250 µl) was added to each residue and the samples were vortexed for 60 min. The solutions were centrifuged for 15 min at 13,000 rpm, and transferred to HPLC vials. Each sample was analysed by HPLC by the method described below.
Preparation and extraction of plasma samples from dosed mice
The plasma samples were thawed on ice, and aliquots (250 µl) were immediately transferred to microfuge tubes and deproteinated by addition of acetonitrile (250 µl).
The samples were further processed as described above for the spiked plasma standards. (6).
HPLC method
Data analyses
Peak areas from HPLC analysis of plasma samples were measured and concentrations of cyclopropavir (5) and prodrug (6) were calculated based on the standard curves generated with the plasma spiked samples. The extraction efficiency for each compound was determined by comparing the peak areas for spiked plasma samples with those for standard samples processed with water instead of plasma. The average extraction efficiency was 67% for cyclopropavir (5) and 88% for the prodrug (6). The limit of detection and the limit of quantification, determined as 3× and 5× the intensity of the matrix peaks in the regions of detection of the analytes, were 0.24 µg/ml and 0.40 µg/ml for cyclopropavir (5) and 0.048 µg/ml and 0.080 µg/ml for the prodrug (6), respectively. The pharmacokinetic modelling and analysis was done using the pharmacokinetic modelling program WinNonLin ® (Pharsight Corp., Mountain View, CA, USA).
Results
Antiviral activity
Prodrug (6) inhibited replication of HCMV in two strains of virus, Towne and AD169 (Table 1 ). These studies confirmed that its potency was comparable to ganciclovir, which was used as a control, and was also similar to cyclopropavir (5) as reported previously [14] . These results confirmed that valcyclopropavir (6) was readily hydrolysed to cyclopropavir (5) inside the virus-infected cells or in the culture medium that contained bovine plasma. However, its efficacy relative to cyclopropavir (5) cannot be discerned from these data. Conversion of valcyclopropavir (6) to cyclopropavir (5) in vitro in mouse plasma and whole blood
The prodrug valcyclopropavir (6) was converted into the parent drug, cyclopropavir (5) when incubated at 37°C in mouse blood or plasma with a half-life of 1 h 20 min and 40.4 min, respectively ( Figure 3 and Table 2 ). At 0°C the conversion was more than an order of magnitude slower, with estimated half-lives in blood and plasma of 22 h and 12 h, respectively. In a control experiment, blood and plasma samples were processed immediately after spiking with the prodrug (no incubation). The level of the cyclopropavir peak detected in those samples corresponded to a 3.7% and 9.0% conversion of valcyclopropavir (6) to cyclopropavir (5) in plasma and blood, respectively. This is assumed to take place during the plasma preparation and sample processing, and should not affect the overall kinetic parameters observed for the in vitro or in vivo metabolism of the prodrug (6), as it is the same for all incubation/sampling times. In our opinion, this small conversion does not warrant correction of the dose-dependent pharmacokinetic parameters for the prodrug (6).
Intravenous dosing
The average plasma concentration of the prodrug (6) and cyclopropavir (5) are plotted in Figure 4 .
Prodrug (6)
The plasma concentration data for prodrug (6) were fitted into a single compartment bolus IV first order elimination model ( Figure 5A ).
The best fit curve is presented in Figure 6A and the best fit pharmacokinetic parameters are presented in Table 3 . Analysis of the plasma concentration profile suggested that the prodrug (6) is converted by a fast process to cyclopropavir (5) . At the same time, some amount of the prodrug (6) remains in a depot compartment, and is released by a slow process. This results in a large half-life and volume of distribution parameter in the single compartment model (Table 3) . Therefore, the data for the prodrug (6) , was fitted to a two compartment bolus IV first order elimination model ( Figure 5B ). The best fit graph and corresponding parameters are presented in Figure 6B and Table 4 . The parameters are more consistent with the properties expected of the prodrug (6) . The lack of very early time points resulted in high coefficients of variability, especially of the parameters highly influenced by K 12 , that is, the rate constant for transfer from compartment 1 to compartment 2.
Cyclopropavir (5)
The plasma concentration of cyclopropavir (5) was first modelled using a single compartment first order Figure 5 . Single and two compartment bolus intravenous first order elimination models showing plasma concentration data for prodrug (6) (A) Single compartment bolus intravenous (IV) first order elimination model. C is the plasma concentration in mg/l, D is the dose in mg/kg, V is the apparent volume of distribution in l, K 10 is the elimination rate constant in l/min and T is the time in min. (B) Two compartment bolus IV first order elimination model. C is the plasma concentration in mg/l, A=D/V•(α-K 21 )/(α-β) and B=-D/V•(β-K 21 )/(α-β). The α and β are the roots of the quadratic equation r•r+(K 12 +K 21 +K 10 )•r+K 21 •K 10 =0, D is the dose in mg/kg, V is the apparent volume of distribution in l, K 12 is the rate constant for transfer from compartment 1 to compartment 2 in l/min, K 21 is the rate constant for transfer from compartment 2 to compartment 1 in l/min, K 10 is the elimination rate constant in l/min and T is the time in min.
Bolus IV
elimination model, in which the last three data points were used to estimate the terminal elimination rate constant, β ( Figure 7A) . The pharmacokinetic parameters based on this analysis are presented in Table 4 . The time dependence of the cyclopropavir (5) plasma concentration was also assessed by using a two compartment model described in Figure 8 .
The best fit graph and corresponding parameters are presented in Figure 7B and Table 5 . The pharmacokinetic parameters obtained by this analysis are in good overall agreement with the corresponding pharmacokinetic parameters, obtained by the single compartment method (Table 6 ). However, because the elimination of the prodrug (6) does not follow first order kinetics, there is significant uncertainty in the estimation of the input rate constant K 01 .
Oral dosing
The results of the plasma sample analysis after a single oral dose of 49.2 mg of prodrug (6) in mice is presented in Figure 9 . No prodrug (6) was detected in the oral samples (limit of detection 0.048 µg/ml). The absorption phase took <10 min and was not observed. The log 10 of the observed experimental cyclopropavir (5) concentrations demonstrated an overall linear decrease ( Figure 9B , red line). The data was fitted into a first order elimination non-compartmental model. The model-predicted and experimental cyclopropavir concentrations are shown in Table 7 , and are also shown plotted in semilog form in Figure 9B . The pharmacokinetic parameters derived from the above model are presented in Table 8 . The prodrug (6) oral bioavailability, calculated according to the formula oral bioavailability %=(IV AUC /oral AUC )(IV dose/ oral dose)×100, was found to be very high at 95.3%. Table 4 . Two compartment first order distribution and elimination pharmacokinetic parameters for prodrug (6) 
Discussion
Chemistry
The previously described [17] tetrahydropyranyl (THP) cyclopropavir (7) , which is available from cyclopropavir in two steps (73% yield) served as a convenient starting material for synthesis of valcyclopropavir (6; Figure 1B ). The method described [2] for synthesis of valacyclovir (1) was followed. Reaction of 7 with N-(tbutoxycarbonyl)-l-valine anhydride (BOCVal) 2 [3] , prodrug (6) is a mixture of two stereoisomers. The stereoisomeric ratio of 2 determined from the 1 H NMR spectrum is 2:1.
Bolus IV 0 K 10 K 01 1 In this model, 0 is the valcyclopropavir (6) occupied compartment, 1 is the main sampling compartment, C is the plasma concentration of 5 in the sampling compartment in mg/l, D is the dose in mg/kg (for simplification of the calculation a dose of 16.2 mg/kg of cyclopropavir (5) was used, which is equivalent to a valcyclopropavir dose of 24.6 mg/kg), V is the apparent volume of distribution in l, K 01 is the first order input rate constant (that is, the rate constant for conversion of prodrug (6) to cyclopropavir (5) in l/min), K 10 is the rate constant for elimination of cyclopropavir (5) from the plasma compartment in l/min and T is the time from the prodrug (6) dosing in min. IV, intravenous.
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Pharmacokinetic studies
Prodrug (6) is converted to cyclopropavir (5) in vitro in mouse whole blood and blood plasma, and in vivo after both IV and oral administration. Prodrug (6) is quickly and efficiently absorbed by the gastrointestinal tract, with oral bioavailability of 95%. The high apparent volume of distribution of 5 after both IV and oral dosing with prodrug (6) is suggestive of possible sequestering of either 6 or 5 in non-sampling compartments. The pharmacokinetic profile of prodrug (6) after IV dosing also supports the possibility of non-uniform distribution of 6 with sequestering outside of the plasma compartment. Table 8 . Pharmacokinetic parameters of cyclopropavir (5) after oral dosing of prodrug (6) In this analysis, a complete conversion of the bioavailable prodrug (6) to cyclopropavir (5) was assumed, which would result in a dose equivalent to 32.4 mg/kg of cyclopropavir (5) . AUC ∞ , area under the curve at infinity; Cl, total plasma clearance; C max , maximum plasma concentration; T 1/2λz , half-life of oral elimination phase; T max , time of maximum plasma concentration; V z , volume of distribution based on the terminal phase; λ z , rate constant of oral elimination phase.
